Lithium, an autophagy modulator commonly used in the treatment of bipolar disorder, has demonstrated efficacy in preventing alpha-synuclein-mediated protein accumulation and aggregation, as well as protecting neurons from oxidative-stress-induced cell death in models of Parkinson’s disease [57]. Here, SNCA is linked to Parkinson disease.